# OnCo record idea-prostate-metastatic-presentation-as-the-screening-endpoint (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-prostate-metastatic-presentation-as-the-screening-endpoint/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-prostate-metastatic-presentation-as-the-screening-endpoint" ;
  schema:name "Judge a prostate screening programme on metastatic presentation, not on incidence or mortality"@en ;
  schema:alternateName "metastasis-free survival screening endpoint prostate"@en, "metastatic presentation as screening outcome"@en ;
  schema:description "Screening trials are judged on deaths, which take fifteen years to count, and on cancers found, which is the wrong direction. Preventing a man from turning up with cancer already in his bones happens three times as often as preventing a death, arrives years earlier, and is the outcome he cares about."@en ;
  schema:url <https://onco.cc/ideas/idea-prostate-metastatic-presentation-as-the-screening-endpoint/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  onco:tag "prostate-evidence" ;
  onco:related <https://onco.cc/ideas/idea-prev-mri-first-prostate-screening-prs/>, <https://onco.cc/ideas/idea-prev-prs-screening-start-age/>, <https://onco.cc/roadmaps/early-detection-roadmap/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-low-risk/>, <https://onco.cc/cancers/prostate-intermediate-risk/>, <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:sections <https://onco.cc/fronts/early-detection/>, <https://onco.cc/fronts/prevention/> ;
  onco:technologies <https://onco.cc/technologies/prostate-screening-psa-mri/>, <https://onco.cc/technologies/mri/> ;
  onco:terms <https://onco.cc/terms/screening/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/overdiagnosis/>, <https://onco.cc/terms/metastasis-free-survival/>, <https://onco.cc/terms/lead-time-bias/>, <https://onco.cc/terms/overtreatment/>, <https://onco.cc/terms/number-needed-to-screen/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-early-detection/>, <https://onco.cc/bottlenecks/b-overdiagnosis/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-prevention-adoption/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-uspstf-prostate-screening-jama-2018/>, <https://onco.cc/key-papers/paper-schroder-erspc-screening-mortality-nejm-2009/>, <https://onco.cc/key-papers/paper-draisma-lead-time-overdiagnosis-psa-jnci-2009/>, <https://onco.cc/key-papers/paper-martin-jama/>, <https://onco.cc/key-papers/paper-goteborg-2-n-engl-j-med-2022/>, <https://onco.cc/key-papers/paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014/> .